Catalyst Pharmaceuticals Inc
CPRXHealthcare|Biotechnology|USA
$31.48
+0.00 (+0.00%)
DCF (FCF)
$21.18
Tangible Book
$7.29
Graham Number
$18.16
Earnings Power
$15.91
About
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Stock Price
+44.1%(1Y)
Pipeline Summary
42 total trials7
Phase 1
12
Phase 2
8
Phase 3
0
Phase 4
Recruiting: 5Completed: 25NO_LONGER_AVAILABLE: 1APPROVED_FOR_MARKETING: 1Terminated: 8Unknown: 1Active: 1
Active Trials (6)
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
NCT06564974Duchenne Muscular Dystrophy
Recruiting
Enrollment: 250 participants
Blue Light Cystoscopy With Cysview® Registry
NCT02660645Bladder Cancer
Recruiting
Enrollment: 4,400 participants
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC
Phase 1Recruiting
Enrollment: 265 participants
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT05796570Acute Myeloid Leukemia
Phase 2Recruiting
Enrollment: 37 participants
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
NCT05556824Gastroesophageal Reflux
Phase 2Active
Enrollment: 247 participants
BioScore
5.6/10
Watchlist
Ownership
Recent Insider Trades
Harper MollySELL
2025-12-1226,746 shares @ $23.25
Del Carmen JeffreySELL
2025-11-2610,983 shares @ $23.33
Elsbernd BrianSELL
2025-11-1240,000 shares @ $22.7
Elsbernd BrianSELL
2025-09-0830,000 shares @ $20.3
Elsbernd BrianSELL
2025-09-0450,000 shares @ $19.74
Recent News
2026-07-09 22:00:12
2026-07-08 18:00:10
2026-06-25 18:00:06
2026-06-24 19:00:04
Data last updated: Jul 12, 2026, 07:37 PM